SKYRIZI® (risankizumab-rzaa) Results for Psoriatic Arthritis

Relief of psoriatic arthritis symptoms

In clinical trials with SKYRIZI, the majority of patients felt a 20% improvement and significant relief in PsA symptoms, including joint pain, stiffness and swelling at 24 weeks; on average, patients experienced less fatigue.^*

^*Based on a scale made by the American College of Rheumatology.

In another study, a majority of patients who continued taking SKYRIZI saw a 20% improvement in their PsA symptoms even at 2 years.^†

^†In a less rigorous study, patients and physicians were aware of SKYRIZI treatment, which may have influenced these results at 2 years.

Click on the areas below to see real results:

A MAJORITY OF THOSE WHO ALSO HAD PLAQUE PSORIASIS SAW90% clearer skin

A majority of people noticedIMPROVEMENTin swelling of fingers and toes for those with dactylitis (also called sausage fingers)

A majority of people feltsignificant relief of theirPsA symptoms including joint pain, tenderness, stiffness and swelling at week 24

Nearly half of people experiencedIMPROVEMENTin areas like the heel and elbow for those with enthesitis

In clinical trials at 24 weeks, people taking 150mg of SKYRIZI were evaluated.

Living every day with PsA

The inflammation in the joints can cause pain, stiffness, swelling, and fatigue.

These PsA symptoms can make everyday activities more difficult to do. SKYRIZI is proven to help reduce this type of inflammation.

Whether it’s a walk in the park, a quick game of catch, or cooking dinner for family and friends—completing everyday activities can become more achievable thanks to SKYRIZI.